International Stem Cell Corp Files 8-K on Security Holder Vote Matters
Ticker: ISCO · Form: 8-K · Filed: Nov 18, 2025 · CIK: 1355790
| Field | Detail |
|---|---|
| Company | International Stem Cell Corp (ISCO) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
ISC filed an 8-K for a shareholder vote on 6/17/25. Keep an eye on the outcome.
AI Summary
International Stem Cell Corporation filed an 8-K on November 18, 2025, reporting on events that occurred on June 17, 2025. The filing pertains to a submission of matters to a vote of security holders. The company, formerly known as BTHC III INC., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing indicates a formal process where security holders are being asked to vote on specific corporate matters, which could impact the company's governance and future direction.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not an indication of immediate financial distress or significant operational change.
Key Players & Entities
- International Stem Cell Corporation (company) — Registrant
- BTHC III INC. (company) — Former company name
- June 17, 2025 (date) — Date of earliest event reported
- November 18, 2025 (date) — Date of report
FAQ
What specific matters are being submitted for a vote of security holders?
The filing does not specify the exact matters to be voted on, only that a submission of matters to a vote of security holders is being reported.
When did the events related to the security holder vote occur?
The earliest event reported in relation to the security holder vote occurred on June 17, 2025.
What is the company's primary business classification?
The company is classified under Pharmaceutical Preparations (SIC code 2834).
Where is International Stem Cell Corporation headquartered?
The company's principal executive offices are located at 9745 Businesspark Ave, San Diego, California 92131.
Has the company's name changed previously?
Yes, the company was formerly known as BTHC III INC., with a date of name change on March 10, 2006.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 14.2 · Accepted 2025-11-18 17:18:02
Filing Documents
- intlstemcell_8k.htm (8-K) — 33KB
- 0001683168-25-008521.txt ( ) — 189KB
- isco-20250617.xsd (EX-101.SCH) — 3KB
- isco-20250617_lab.xml (EX-101.LAB) — 33KB
- isco-20250617_pre.xml (EX-101.PRE) — 22KB
- intlstemcell_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
ITEM 5.07 Submission of Matters to a Vote of Security Holders International Stem Cell Corporation (the "Company") held its Annual Meeting of Stockholders on June 17, 2025. The stockholders considered two proposals, which are described in more detail in the Company's definitive proxy statement dated April 24, 2025. Proposal 1: Election of four directors to hold office until the 2026 Annual Meeting: A. Directors elected by holders of Series D Preferred Stock: FOR WITHHELD Andrey Semechkin 2,457,143 0 Russell Kern 2,457,143 0 B. Directors elected by holders of all shares of stock (including shares of preferred stock voting on an as-converted basis): FOR WITHHELD Donald A. Wright 7,772,429 19,267 Paul V. Maier 7,772,429 19,267 Broker Non-Votes: none All of the foregoing candidates were elected. Proposal 2: To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement. FOR Against ABSTAIN 7,715,844 73,393 2,459 Broker Non-Votes: none Proposal 3: To vote, on an advisory basis, of the frequency of advisory votes on executive compensation. 1 Year 2 Years 3 Years ABSTAIN 142,581 50,443 7,593,833 4,839 Broker Non-Votes: none 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INTERNATIONAL STEM CELL CORPORATION Date: November 18, 2025 By: /s/ Russell Kern Russell Kern Executive Vice President, Chief Scientific Officer and Principal Financial Officer 3